Is ASTH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The shift toward full-risk contracts, with revenue (ttm) at ~$3.84B, up ~59% year over year. The bear case rests on the core risk is structural: with operating margin under 3%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Analysts covering it are spread from $41.00 to $65.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The core risk is structural: with operating margin under 3%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $41.00, +14.7% from the $35.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The shift toward full-risk contracts. Astrana has been steadily moving members from shared-savings and partial-risk arrangements into full-risk capitation, which is what drove adjusted EBITDA up ~43% in Q2 2026 on ~49% revenue growth. The most optimistic analyst target on ASTH is $65.00, +81.8% from the $35.76 price. That figure is only reachable if this thesis works close to its best case.

The core risk is structural: with operating margin under 3%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Leverage compounds this, with total debt of ~$979 million against ~$401 million of cash after the Prospect transaction, so integration missteps land on a balance sheet with less slack than before. Concentration is real on two axes, geography (California remains the dominant market) and counterparty (a small number of health plans account for a large share of revenue, and contract renegotiation or non-renewal would be material). Regulatory exposure runs in several directions at once: CMS rate notices and the v28 risk-adjustment phase-in set the revenue baseline, federal scrutiny of Medicare Advantage risk-adjustment coding continues industry-wide, and California legislation targeting management-services organizations and the corporate practice of medicine could reach Astrana's structure directly. Separately, an employment class action alleging meal and rest period violations (Case No. 26STCV21467, Los Angeles County Superior Court) is pending against Astrana Health Management; it is a wage-and-hour matter rather than a securities case, and no filed securities-fraud class action was identified as of August 2026. The most pessimistic published target is $41.00, +14.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Astrana Health is a physician-centric value-based care company that organizes independent doctors into risk-bearing networks and takes capitated payments from health plans.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The shift toward full-risk contracts) stalling in the reported numbers rather than in the narrative, the risk above (the core risk is structural: with operating margin under 3%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

ASTH is Astrana Health, Inc., a Nasdaq-listed, physician-centric value-based healthcare company headquartered in California. It organizes independent physicians into risk-bearing networks and contracts with health plans on a capitated basis, primarily serving Medicare Advantage and Medicaid members.

Yes. The company traded as Apollo Medical Holdings under the ticker AMEH before rebranding to Astrana Health in 2024, at which point the ticker changed to ASTH. It is the same operating business with the same corporate history, not a new listing.

Yes, on a GAAP basis, which distinguishes it from several value-based care peers. Trailing twelve-month net income is ~$40.6 million on ~$3.84 billion of revenue, or roughly a 1% net margin, and trailing free cash flow is ~$94 million. The profitability is real but very thin relative to revenue.